Robert M Grant, Javier R Lama, Peter L Anderson, Vanessa McMahan, Albert Y Liu, Lorena Vargas, Pedro Goicochea, Martín Casapía, Juan Vicente Guanira-Carranza, Maria E Ramirez-Cardich, Orlando Montoya-Herrera, Telmo Fernández, Valdilea G Veloso, Susan P Buchbinder, Suwat Chariyalertsak, Mauro Schechter, Linda-Gail Bekker, Kenneth H Mayer, Esper Georges Kallás, K Rivet Amico, Kathleen Mulligan, Lane R Bushman, Robert J Hance, Carmela Ganoza, Patricia Defechereux, Brian Postle, Furong Wang, J Jeff McConnell, Jia-Hua Zheng, Jeanny Lee, James F Rooney, Howard S Jaffe, Ana I Martinez, David N Burns, David V Glidden
BACKGROUND: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. METHODS: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections...
December 30, 2010: New England Journal of Medicine